JP5025201B2 - Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant - Google Patents

Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant Download PDF

Info

Publication number
JP5025201B2
JP5025201B2 JP2006253556A JP2006253556A JP5025201B2 JP 5025201 B2 JP5025201 B2 JP 5025201B2 JP 2006253556 A JP2006253556 A JP 2006253556A JP 2006253556 A JP2006253556 A JP 2006253556A JP 5025201 B2 JP5025201 B2 JP 5025201B2
Authority
JP
Japan
Prior art keywords
added
genus
extract
agent
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006253556A
Other languages
Japanese (ja)
Other versions
JP2008074730A (en
Inventor
雅樹 荒島
陽子 浅野
浩子 吉田
彰 葉谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2006253556A priority Critical patent/JP5025201B2/en
Priority to PCT/JP2007/067415 priority patent/WO2008035572A1/en
Publication of JP2008074730A publication Critical patent/JP2008074730A/en
Application granted granted Critical
Publication of JP5025201B2 publication Critical patent/JP5025201B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Description

本発明は、保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤に関する。さらに詳しくは、サガリバナ属植物もしくはホウガンノキ属植物より選ばれる1種又は2種以上の植物の抽出物を有効成分とする保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤に関する。   The present invention relates to a humectant, an anti-aging agent, a whitening agent, an anti-inflammatory agent, and an antioxidant. More specifically, the present invention relates to a moisturizer, an anti-aging agent, a whitening agent, an anti-inflammatory agent, and an anti-oxidant containing as an active ingredient an extract of one or two or more kinds of plants selected from the plant of the genus Sagaribana or the genus Botanus.

加齢に伴う皮膚の弾性低下及びシワ、シミといった老化症状の要因として、細胞機能低下、コラーゲン等の細胞外マトリックス成分の減少や変性、紫外線によるメラニン産生や色素沈着及び細胞の酸化傷害等が挙げられる。このような老化症状を防止・改善するために、従来、様々な有効成分の検索及び配合検討がなされてきた。細胞賦活剤としては、ポンカンのエッセンス(特許文献1参照)、コラゲナーゼ阻害剤としては、ジカルボン酸(特許文献2参照)、コラーゲン産生促進剤としては、ブナ科ブナ属植物の木の芽からの抽出物(特許文献3参照)、美白剤としては、白鶴霊芝の水及び/又は有機溶媒抽出物(特許文献4参照)、抗酸化剤としては、サルオガセ科サルオガセ属植物の抽出物(特許文献5参照)、抗炎症剤としては、茶ポリフェノール類(特許文献6参照)、アロマターゼ活性促進剤としては、クロレラの抽出物(特許文献7参照)が知られている。   Factors of skin elasticity with age and aging symptoms such as wrinkles and spots include decreased cell function, decreased or denatured extracellular matrix components such as collagen, melanin production and pigmentation by UV rays, and oxidative damage to cells. It is done. In order to prevent and ameliorate such aging symptoms, various active ingredients have been searched for and studied for compounding. As a cell activator, the essence of Ponkan (see Patent Document 1), as a collagenase inhibitor, a dicarboxylic acid (see Patent Document 2), and as a collagen production promoter, an extract from a bud of a beech family, As a whitening agent, a water and / or organic solvent extract of white crane reishi (see Patent Document 4), and as an antioxidant, an extract of a plant belonging to the genus Sarogase (see Patent Document 5). Tea polyphenols (see Patent Document 6) are known as anti-inflammatory agents, and chlorella extracts (see Patent Document 7) are known as aromatase activity promoters.

特開2001−131045号公報JP 2001-131045 A 特開平9−124472号公報Japanese Patent Laid-Open No. 9-124472 特開平10−203952号公報Japanese Patent Laid-Open No. 10-203952 特開2003−89630号公報JP 2003-89630 A 特開平10−182413号公報Japanese Patent Laid-Open No. 10-182413 特開平6−9391号公報JP-A-6-9391 特開2004−189609号公報JP 2004-189609 A 特開2003−226613号公報JP 2003-226613 A

天然由来成分は、様々な薬理作用や美容効果を有することが知られ、これまでにも多数の植物や菌類などが皮膚外用剤や飲食品などの分野に幅広く応用されている。しかし、天然由来成分の中には未だその効果が知られていないものも数多く存在し、優れた保湿作用、抗老化作用、抗炎症作用、あるいは抗酸化作用を有する有効成分の開発が期待されていた。本発明は、このような有効成分を見出すためになされたものであり、皮膚外用剤や飲食品などの分野に幅広く応用が可能な保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤を提供することを課題とする。   Naturally-derived components are known to have various pharmacological and cosmetic effects, and so far many plants and fungi have been widely applied to fields such as external preparations for skin and foods and drinks. However, there are many naturally-derived ingredients whose effects are not yet known, and the development of active ingredients with excellent moisturizing, anti-aging, anti-inflammatory, or antioxidant effects is expected. It was. The present invention has been made in order to find such an active ingredient, and is a moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and anti-inflammatory agent that can be widely applied in the fields of external preparations for skin and foods and drinks. It is an object to provide an oxidizing agent.

本発明者らは、上記の課題を解決するために、保湿作用、抗老化作用、美白作用、抗炎症作用、及び抗酸化作用に関して、天然由来の種々の物質について検討を行った。その結果、サガリバナ属植物もしくはホウガンノキ属植物より選ばれる1種又は2種以上の植物の抽出物に優れた保湿作用、抗老化作用、美白作用、抗炎症作用、及び抗酸化作用を見出し、さらに検討を重ね、本発明を完成するに至った。   In order to solve the above problems, the present inventors have studied various naturally-derived substances with respect to a moisturizing action, an anti-aging action, a whitening action, an anti-inflammatory action, and an antioxidant action. As a result, we found excellent moisturizing action, anti-aging action, whitening action, anti-inflammatory action, and anti-oxidation action for one or more plant extracts selected from the genus Sagaribana or Botanus. As a result, the present invention was completed.

すなわち、本発明は、サガリバナ属植物もしくはホウガンノキ属植物より選ばれる1種又は2種以上の植物の抽出物を有効成分とする保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤に関する。   That is, the present invention relates to a moisturizing agent, an anti-aging agent, a whitening agent, an anti-inflammatory agent, and an anti-oxidant comprising as an active ingredient an extract of one or two or more kinds of plants selected from the plant of the genus Sagaribana or the genus Botanus. About.

本発明によれば、優れた効果を有する保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤を提供することができる。また、これらを皮膚外用剤や食品に配合することにより、シワ,タルミ,肌のハリの低下,シミ,クスミ,小ジワ,乾燥など様々な皮膚症状の防止・改善に優れた効果を発揮する組成物を提供することができる。   According to the present invention, it is possible to provide a moisturizer, an anti-aging agent, a whitening agent, an anti-inflammatory agent, and an antioxidant that have excellent effects. In addition, by blending these into topical skin preparations and foods, a composition that exhibits excellent effects in preventing and improving various skin symptoms such as wrinkles, tarmi, reduction of skin firmness, spots, wrinkles, fine wrinkles, and dryness. Things can be provided.

本発明の原料として用いられる植物は、サガリバナ科(Lecythidaceae)サガリバナ属(Barringtonia)もしくはホウガンノキ属(Couroupita)の植物であればよい。サガリバナ属植物としては、サガリバナ(Barringtonia racemosa)、コバンノアシ(Barringtonia asiatica)などが知られている。ホウガンノキ属の植物としては、ホウガンノキ(Couroupita guianensis)などが知られている。 Plants used as a raw material of the present invention may be any plant of lecythidaceae (Lecythidaceae) barringtonia genus (Barringtonia) or Hougan'noki genus (Couroupita). As plants belonging to the genus Sagaribana, sagaribana ( Barringtonia racemosa ), barn reed ( Barringtonia asiatica ) and the like are known. The Hougan'noki plants of the genus, such as Hougan'noki (Couroupita guianensis) is known.

本発明に用いられる原料となる植物は、サガリバナ属植物もしくはホウガンノキ属植物であれば特に限定されないが、入手が比較的容易なことや有効性などの理由から、コバンノアシ(Barringtonia asiatica)を用いることが有効性の点から特に好ましい。 The plant used as a raw material for the present invention is not particularly limited as long as it is a plant belonging to the genus Sagaribana or the genus Boletus, but for reasons such as being relatively easy to obtain and effective, it is preferable to use Barringtonia asiatica. This is particularly preferable from the viewpoint of effectiveness.

本発明におけるサガリバナ属植物もしくはホウガンノキ属植物の抽出物には、サガリバナ属植物もしくはホウガンノキ属植物の原体や乾燥物も抽出物に含まれるが、各種溶媒を用いて抽出した抽出物を用いるのが好ましい。抽出には、サガリバナ属植物もしくはホウガンノキ属植物の葉、花、種子、根、樹皮、芽などのいずれの部位を用いても構わないが、簡便に利用するには、葉、茎、種子を用いるとよく、有効性の点からは種子を用いるとよい。抽出の際は、生のまま用いてもよいが、抽出効率を考えると、細切、乾燥、粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬するか、超臨界流体や亜臨界流体を用いた抽出方法でも行うことができる。抽出効率を上げるため、撹拌や抽出溶媒中でホモジナイズしてもよい。抽出温度としては、5℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、1時間〜14日間程度とするのが適切である。   In the present invention, the extract of the genus Sagaribana or the genus Botanus includes the original or dried product of the plant of the genus Sagari or genus, but it is possible to use extracts extracted using various solvents. preferable. For extraction, any part of the leaves, flowers, seeds, roots, bark, buds, etc. may be used for extraction, but leaves, stems, and seeds are used for convenient use. It is better to use seeds from the viewpoint of effectiveness. In the extraction, it may be used as it is, but considering the extraction efficiency, it is preferable to perform the extraction after performing processing such as shredding, drying, and pulverization. The extraction can be performed by immersing in an extraction solvent or by an extraction method using a supercritical fluid or a subcritical fluid. In order to increase the extraction efficiency, the mixture may be homogenized in stirring or an extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it to about 1 hour to 14 days.

抽出溶媒としては、水の他、メタノール、エタノール、プロパノール、イソプロパノール等の低級アルコール、1、3−ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリン等の多価アルコール、エチルエーテル、プロピルエーテル等のエーテル類、酢酸ブチル、酢酸エチル等のエステル類、アセトン、エチルメチルケトン等のケトン類などの溶媒を用いることができ、これらより1種又は2種以上を選択して用いる。また、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等を用いてもよい。さらに、水や二酸化炭素、エチレン、プロピレン、エタノール、メタノール、アンモニアなどの1種又は2種以上の超臨界流体や亜臨界流体を用いてもよい。   Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether. And solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia.

サガリバナ属植物もしくはホウガンノキ属植物の上記溶媒による抽出物は、そのままでも使用することができるが、濃縮、乾固した物を水や極性溶媒に再度溶解して使用することもでき、これらの生理作用を損なわない範囲で脱色、脱臭、脱塩等の精製処理やカラムクロマトグラフィー等による分画処理を行った後に用いてもよい。サガリバナ属植物もしくはホウガンノキ属植物の前記抽出物やその処理物及び分画物は、各処理及び分画後に凍結乾燥し、用時に溶解して用いることもできる。   Extracts from the above-mentioned solvents of the genus Sagaribana or Botanus can be used as they are, but the concentrated and dried solids can be used by re-dissolving them in water or a polar solvent. It may be used after performing a purification treatment such as decolorization, deodorization, and desalting, and a fractionation treatment by column chromatography or the like within a range not impairing the above. The said extract of Sagaribana genus plant or Botanus genus plant, its processed material, and the fractionation thing can be freeze-dried after each processing and fractionation, and can also be melt | dissolved and used at the time of use.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする保湿剤は、皮膚や毛髪に対して優れた保湿作用を発揮し、特に皮膚に対する保湿効果が高い。   A moisturizing agent containing as an active ingredient an extract of the genus Sagaribana or Botanus spp. Exhibits an excellent moisturizing effect on the skin and hair, and in particular has a high moisturizing effect on the skin.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする抗老化剤は、優れた細胞賦活効果、コラーゲン産生作用、およびアロマターゼ活性促進作用を有し、老化症状の防止改善に優れた効果を発揮する。アロマターゼは、エストロゲンを産生する際に働く酵素であり、アロマターゼ活性促進作用によりエストロゲンの産生が促進されると、女性ホルモンによる美肌効果や抗老化効果が期待できる。   An anti-aging agent comprising an extract of the genus Sagaribana or Botanus spp. As an active ingredient has an excellent cell activation effect, collagen production action, and aromatase activity promotion action, and exhibits an excellent effect in preventing and improving aging symptoms To do. Aromatase is an enzyme that works when producing estrogen. If the production of estrogen is promoted by an aromatase activity promoting action, a skin beautifying effect and an anti-aging effect by female hormones can be expected.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする美白剤は、シミ・ソバカスといった色素沈着症状の改善に効果を発揮し、特にチロシナーゼ活性の阻害やメラニンの産生抑制に対して優れた効果を発揮する。   A whitening agent containing an extract of the genus Sagaribana or Botanus genus as an active ingredient is effective in improving pigmentation symptoms such as spots and buckwheat, and is particularly effective for inhibiting tyrosinase activity and suppressing melanin production. Demonstrate.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする抗炎症剤は、優れたヒアルロニダーゼ阻害効果を有し、皮膚の炎症を抑え優れた抗炎症作用を発揮する。   An anti-inflammatory agent containing an extract of the genus Sagaribana or Botanus as an active ingredient has an excellent hyaluronidase inhibitory effect, suppresses skin inflammation, and exhibits an excellent anti-inflammatory action.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする抗酸化剤は、優れたフリーラジカル消去効果、およびスーパーオキサイドアニオンの消去効果を有し、皮膚の光老化等を防止して、優れた抗酸化作用を発揮する。   Antioxidants containing extracts of the genus Sagaribana or Botanus spp. As active ingredients have excellent free radical scavenging effects and superoxide anion scavenging effects, and prevent skin photoaging etc. Demonstrate antioxidant effect.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物は、優れた保湿作用、抗老化作用、美白作用、抗炎症作用、及び抗酸化作用を有し、保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤として利用することができる。また、サガリバナ属植物もしくはホウガンノキ属植物の抽出物を有効成分とする保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤は、皮膚に外用する外用組成物だけではなく、毛髪に利用することや経口摂取も可能であり、食品、飲料、あるいは医薬品など幅広く応用することが可能である。   The extract of the genus Sagaribana or the genus Botanus has an excellent moisturizing action, anti-aging effect, whitening action, anti-inflammatory action, and anti-oxidation action, moisturizing agent, anti-aging agent, whitening agent, anti-inflammatory agent, And can be used as an antioxidant. In addition, moisturizers, anti-aging agents, whitening agents, anti-inflammatory agents, and antioxidants that contain extracts of the genus Sagaribana or Botanus genus plant as active ingredients are not only externally applied to the skin, but also to the hair. It can be used or taken orally, and can be widely applied to foods, beverages, pharmaceuticals, and the like.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を皮膚外用剤や食品に配合する際の配合量は、皮膚外用剤や食品の種類や使用目的等によって調整することができるが、効果や安定性などの点から、全量に対して、0.0001〜50.0重量%が好ましく、より好ましくは、0.001〜20.0重量%である。   The amount of sagaribana plant or genus genus plant extract added to skin preparations and foods can be adjusted depending on the type of skin preparations and foods, purpose of use, etc. From the point, 0.0001 to 50.0% by weight is preferable with respect to the total amount, and more preferably 0.001 to 20.0% by weight.

サガリバナ属植物もしくはホウガンノキ属植物の抽出物を配合する皮膚外用剤の剤型は任意であり、例えば、ローションなどの可溶化系、クリームや乳液などの乳化系,カラミンローション等の分散系として提供することができる。さらに、噴射剤と共に充填したエアゾール,リップスティック,ファンデーションなどの種々の剤型で提供することもできる。   The dosage form of the external preparation for skin containing the extract of the genus Sagaribana or the genus Botanus is arbitrary. For example, it is provided as a solubilizing system such as lotion, an emulsifying system such as cream or emulsion, or a dispersing system such as calamine lotion. be able to. Further, it can be provided in various dosage forms such as aerosol, lipstick, and foundation filled with a propellant.

なお、上記抽出物を配合する皮膚外用剤には、これらの抽出物の他に必要に応じて、通常医薬品,医薬部外品,皮膚化粧料,毛髪用化粧料及び洗浄料に配合される、油性成分,保湿剤,粉体,色素,乳化剤,可溶化剤,洗浄剤,紫外線吸収剤,増粘剤,薬剤,香料,樹脂,防菌防黴剤,アルコール類等を適宜配合することができる。また、本発明の効果を損なわない範囲において、他の保湿剤、抗老化剤、美白剤、抗炎症剤、あるいは抗酸化剤との併用も可能である。   In addition, the external preparation for skin blended with the extract is usually blended with pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents as needed, in addition to these extracts. Oily ingredients, moisturizers, powders, pigments, emulsifiers, solubilizers, detergents, UV absorbers, thickeners, drugs, fragrances, resins, antibacterial / antifungal agents, alcohols, etc. can be added as appropriate. . In addition, other moisturizers, anti-aging agents, whitening agents, anti-inflammatory agents, or antioxidants can be used in combination as long as the effects of the present invention are not impaired.

また、サガリバナ属植物もしくはホウガンノキ属植物の抽出物を配合する食品の剤型は任意であるが、粉末剤、顆粒剤、カプセル剤、液剤などの種々の剤型で提供することもでき、必要に応じて、医薬品・医薬部外品・食品などに配合される、油性成分,保湿剤,粉体,乳化剤,可溶化剤,増粘剤,薬剤,香料,防菌防黴剤,アルコール類,砂糖,練乳,小麦粉,食塩,ブドウ糖,鶏卵,バター,マーガリン,水飴,カルシウム,鉄分,調味料,香辛料、ビタミンA及びそれらの誘導体、カロテノイド類、リボフラビン及びその誘導体、ビタミンB類及びそれらの塩若しくは誘導体、アスコルビン酸及びその誘導体、コバラミン類、ビタミンE及びそれらの誘導体、ビタミンK、アデノシン及びその誘導体、フラボノイド類及びタンニン類を配合することもできる。さらに、本発明の効果を損なわない範囲において、他の保湿剤、抗老化剤、美白剤、抗炎症剤、あるいは抗酸化剤との併用も可能である。   Moreover, the dosage form of the food containing the extract of the genus Sagaribana or the genus Botanus is arbitrary, but it can be provided in various dosage forms such as powders, granules, capsules, liquids, etc. The oily ingredients, moisturizers, powders, emulsifiers, solubilizers, thickeners, drugs, fragrances, antibacterial and antifungal agents, alcohols, sugar , Condensed milk, flour, salt, glucose, chicken egg, butter, margarine, starch syrup, calcium, iron, seasoning, spice, vitamin A and derivatives thereof, carotenoids, riboflavin and derivatives thereof, vitamin B and salts or derivatives thereof , Ascorbic acid and its derivatives, cobalamins, vitamin E and their derivatives, vitamin K, adenosine and its derivatives, flavonoids and tannins It is also possible to focus. Furthermore, it can be used in combination with other moisturizers, anti-aging agents, whitening agents, anti-inflammatory agents, or antioxidants as long as the effects of the present invention are not impaired.

以下に、サガリバナ属植物もしくはホウガンノキ属植物の抽出物の製造例、各作用を評価するための試験、皮膚外用剤や食品としての処方例、使用試験について詳細に説明するが、本発明の技術的範囲はこれによってなんら限定されるものではない。   The production examples of the extracts of the genus Sagaribana or the genus Botanus, the tests for evaluating each action, the formulation examples as external preparations for skin and foods, and the use tests will be described in detail below. The range is not limited by this.

[抽出方法1]
サガリバナ属植物もしくはホウガンノキ属植物を乾燥させて粉砕し、サンプル質量の20倍量の50質量%エタノールを加え、室温で撹拌しながら2時間抽出した。得られた抽出液を濾過して不溶物を取り除き、減圧濃縮後、凍結乾燥を行って、抽出物を得た。
[Extraction method 1]
The genus Sagaribana or the genus Botanus was dried and pulverized, added with 20% by mass of 50% by mass of ethanol and extracted for 2 hours while stirring at room temperature. The obtained extract was filtered to remove insolubles, concentrated under reduced pressure, and then freeze-dried to obtain an extract.

[抽出方法2]
サガリバナ属植物もしくはホウガンノキ属植物を乾燥させて粉砕し、サンプル質量の20倍量の精製水を加え、オートクレーブにより20分間、120℃に加温して抽出した。得られた抽出液から、温度の高い状態を保ちながら吸引濾過により不溶物を取り除いた後、凍結乾燥を行って、抽出物を得た。
[Extraction method 2]
The genus Sagaribana or the genus Botanus was dried and pulverized, purified water having an amount 20 times the mass of the sample was added, and the mixture was extracted by heating to 120 ° C. for 20 minutes using an autoclave. From the obtained extract, insoluble matters were removed by suction filtration while maintaining a high temperature state, and then lyophilized to obtain an extract.

<真皮線維芽細胞賦活作用の評価>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のように真皮線維芽細胞賦活作用を評価した。
<Evaluation of dermal fibroblast activation effect>
Using the ethanol extract obtained by the extraction method 1 as a sample, the dermal fibroblast activation action was evaluated as follows.

倉敷紡績(株)製正常ヒト真皮線維芽細胞を、1ウェルあたり2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、ダルベッコ改変イーグル培地(DMEM)に1質量%のウシ胎児血清(FBS)を添加したものを用いた。24時間培養後、1質量%FBS添加DMEM培地により表1に示す各試料濃度に調整したサンプル培養液に交換し、さらに48時間培養した。上清を除いた後、3−(4,5−ジメチル−2−チアゾリル)−2,5−ジフェニルテトラゾリウムブロミド(MTT試薬)を400μg/ml含有する培地に交換し、約2時間培養した。その後、テトラゾリウム環の開環により生じるフォルマザンを2−プロパノールにより抽出し、マイクロプレートリーダーで550nmの吸光度を測定した。同時に、濁度として650nmにおける吸光度を測定し、両測定値の差により細胞賦活作用を評価した。 Normal human dermal fibroblasts manufactured by Kurashiki Boseki Co., Ltd. were seeded in a 96-well microplate so that there were 2.0 × 10 4 cells per well. As the seeding medium, Dulbecco's modified Eagle medium (DMEM) to which 1% by mass of fetal bovine serum (FBS) was added was used. After culturing for 24 hours, the medium was replaced with a sample culture solution adjusted to each sample concentration shown in Table 1 with 1% by mass FBS-added DMEM medium, and further cultured for 48 hours. After removing the supernatant, the medium was replaced with a medium containing 400 μg / ml of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT reagent) and cultured for about 2 hours. Thereafter, formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.

得られた結果を、試料無添加のコントロールにおける細胞賦活作用を100としたときの相対値により表1に示す。   The obtained results are shown in Table 1 in terms of relative values when the cell activation effect in the sample-free control is taken as 100.

Figure 0005025201
Figure 0005025201

表1より明らかなように、試料を添加した培地では、有意な真皮線維皮芽細胞賦活効果が認められた。   As is clear from Table 1, a significant dermal fibroblast activation effect was observed in the medium to which the sample was added.

<表皮細胞賦活作用の評価>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のように表皮細胞賦活作用を評価した。
<Evaluation of epidermal cell activation effect>
Using the ethanol extract obtained by the extraction method 1 as a sample, the epidermal cell activation action was evaluated as follows.

ヒト表皮未全角化細胞を、1ウェルあたり2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、ダルベッコ改変イーグル培地(DMEM)に5質量%のウシ胎児血清(FBS)を添加したものを用いた。24時間培養後、5質量%FBS添加DMEM培地により表2に示す各試料濃度に調整したサンプル培養液に交換し、さらに24時間培養した。上清を除いた後、MTT試薬を100μg/ml含有する培地に交換して約2時間培養した。その後、テトラゾリウム環の開環により生じるフォルマザンを2−プロパノールにより抽出し、マイクロプレートリーダーで550nmの吸光度を測定した。同時に、濁度として650nmにおける吸光度を測定し、両測定値の差により細胞賦活作用を評価した。 Human epidermal non-keratinized cells were seeded in a 96-well microplate so that there were 2.0 × 10 4 cells per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight fetal bovine serum (FBS). After culturing for 24 hours, the culture medium was replaced with a sample culture solution adjusted to each sample concentration shown in Table 2 with 5% by mass FBS-added DMEM medium, and further cultured for 24 hours. After removing the supernatant, the medium was replaced with a medium containing 100 μg / ml of MTT reagent and cultured for about 2 hours. Thereafter, formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.

得られた結果を、試料無添加のコントロールにおける細胞賦活作用を100としたときの相対値により表2に示す。   The obtained results are shown in Table 2 by relative values when the cell activation effect in the control with no sample added is defined as 100.

Figure 0005025201
Figure 0005025201

表2より明らかなように、試料を添加した培地では、有意な表皮細胞賦活効果が認められた。   As is clear from Table 2, a significant epidermal cell activation effect was observed in the medium to which the sample was added.

<真皮繊維芽細胞コラーゲン産生作用の評価>
上記抽出方法1及び2で得られたエタノール抽出物と熱水抽出物を試料として、以下のように真皮線維芽細胞コラーゲン産生作用を評価した。
<Evaluation of dermal fibroblast collagen production>
Using the ethanol extract and hot water extract obtained by the extraction methods 1 and 2 as samples, the dermal fibroblast collagen production action was evaluated as follows.

正常ヒト真皮繊維芽細胞を、1ウェルあたり2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、ダルベッコ改変イーグル培地(DMEM)に5質量%のウシ胎児血清(FBS)を添加したものを用いた。24時間培養後、0.5質量%FBS添加DMEM培地により表3に示す試料濃度に調整した培養液に交換し、さらに24時間培養した。 Normal human dermal fibroblasts were seeded in a 96-well microplate at 2.0 × 10 4 cells per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight fetal bovine serum (FBS). After culturing for 24 hours, the medium was replaced with a culture solution adjusted to the sample concentration shown in Table 3 with 0.5% by mass FBS-added DMEM medium, and further cultured for 24 hours.

培養上清中に分泌されたタイプI及びタイプШのコラーゲン定量にはELISA法を用い、最後は標識されたペルオキシダーゼに対し2,2’−アジノビス(3−エチルベンゾチアゾリン−6−スルホン酸)ジアンモニウム塩(ABTS)および過酸化水素を添加して反応させた後、マイクロプレートリーダーにより405nmの吸光度を測定した。   The ELISA method was used for the quantification of type I and type IV collagen secreted into the culture supernatant, and finally 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) disulfide for labeled peroxidase. After adding ammonium salt (ABTS) and hydrogen peroxide for reaction, absorbance at 405 nm was measured with a microplate reader.

PIERCE社製BCA Protein Assay Kitによりタンパク量を測定し、単位タンパク量当りのタイプI及びタイプШコラーゲン産生量を求めた。   The amount of protein was measured by BCA Protein Assay Kit manufactured by PIERCE, and the amount of type I and type IV collagen produced per unit protein was determined.

得られた結果を、試料無添加のコントロールにおける単位タンパク量あたりのタイプIタイプI及びタイプШのコラーゲン産生量を100としたときの相対値により表3に示す。   The obtained results are shown in Table 3 by relative values when the amount of collagen production of type I type I and type cocoon per unit protein amount in the control with no sample added is defined as 100.

Figure 0005025201
Figure 0005025201

表3より明らかなように、試料を添加した培地では、有意な真皮繊維芽細胞コラーゲン産生効果が認められた。   As is clear from Table 3, in the medium to which the sample was added, a significant dermal fibroblast collagen production effect was observed.

<表皮細胞コラーゲン産生作用の評価>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のように表皮細胞コラーゲン産生作用を評価した。
<Evaluation of epidermal cell collagen production>
Using the ethanol extract obtained by the extraction method 1 as a sample, the epidermal cell collagen producing action was evaluated as follows.

ヒト表皮未全角化細胞を、1ウェルあたり2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、ダルベッコ改変イーグル培地(DMEM)に5質量%のウシ胎児血清(FBS)を添加したものを用いた。24時間培養後、5質量%FBS添加DMEM培地により表4に示す各試料濃度に調整したサンプル培養液に交換し、さらに5日間培養した。 Human epidermal non-keratinized cells were seeded in a 96-well microplate so that there were 2.0 × 10 4 cells per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight fetal bovine serum (FBS). After culturing for 24 hours, the culture medium was replaced with a sample culture solution adjusted to each sample concentration shown in Table 4 with 5% by mass FBS-added DMEM medium, and further cultured for 5 days.

培養上清中に分泌されたタイプIVコラーゲン定量には、IV型コラーゲンに対するモノクローナル抗体(認識部位:α2鎖)およびビオチン化ポリクローナル抗体を用いたサンドイッチELISA法を用い、アビジン化ホースラディッシュペルオキシダーゼを添加し、3,3’,5,5’−テトラメチルベンジジンにより発色させ、マイクロプレートリーダーにより650nmの吸光度を測定した。   For the quantification of type IV collagen secreted in the culture supernatant, avidinized horseradish peroxidase was added using a sandwich ELISA method using a monoclonal antibody against IV collagen (recognition site: α2 chain) and a biotinylated polyclonal antibody. The color was developed with 3,3 ′, 5,5′-tetramethylbenzidine, and the absorbance at 650 nm was measured with a microplate reader.

PIERCE社製BCA Protein Assay Kitによりタンパク量を測定し、単位タンパク量当りのタイプIVコラーゲン産生量を求めた。   The amount of protein was measured by BCA Protein Assay Kit manufactured by PIERCE, and the amount of type IV collagen produced per unit protein was determined.

得られた結果を、試料無添加のコントロールにおける単位タンパク量あたりのタイプIVコラーゲン産生量を100としたときの相対値により表4に示す。   The obtained results are shown in Table 4 by relative values when the type IV collagen production amount per unit protein amount in the control with no sample added is defined as 100.

Figure 0005025201
Figure 0005025201

表4より明らかなように、試料を添加した培地では、有意な表皮細胞コラーゲン産生効果が認められた。   As is clear from Table 4, in the medium to which the sample was added, a significant epidermal cell collagen production effect was observed.

<アロマターゼ活性促進作用の評価>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のようにアロマターゼ活性促進作用を評価した。
<Evaluation of aromatase activity promoting action>
Using the ethanol extract obtained by the extraction method 1 as a sample, the aromatase activity promoting action was evaluated as follows.

表5に示す各試料濃度に調製した試料溶液4μlに、NADP+、MgCl、グルコース−6−ホスフェート、グルコース−6−ホスフェートデヒドロゲナーゼ、およびコントロール昆虫細胞膜タンパクの混合溶液(CPY19/MFC ハイスループット・インヒビター・スクリーニングキット(High Throughput Inhibitor Screening Kit)、BD Biosciences社製)96μlを添加し、10分間37℃に加温した。15nM CPY19(アロマターゼ)、50μM 7−メトキシ−4−トリフルオロメチルクマリン(基質)溶液100μlを添加し、30分間37℃に加温した。100mM トリス塩基75μlを添加し、反応を停止させた。 In 4 μl of the sample solution prepared at each sample concentration shown in Table 5, a mixed solution of NADP +, MgCl 2 , glucose-6-phosphate, glucose-6-phosphate dehydrogenase, and control insect cell membrane protein (CPY19 / MFC high-throughput inhibitor 96 μl of a screening kit (High Throughput Inhibitor Screening Kit), manufactured by BD Biosciences) was added and heated to 37 ° C. for 10 minutes. 100 μl of 15 nM CPY19 (aromatase), 50 μM 7-methoxy-4-trifluoromethylcoumarin (substrate) solution was added and warmed to 37 ° C. for 30 minutes. The reaction was stopped by adding 75 μl of 100 mM Tris base.

励起波長409nm、発光波長530nmにおいて蛍光測定を行った。7−メトキシ−4−トリフルオロメチルクマリンはCYP19により分解され、7−ヒドロキシ−4−トリフルオロメチルクマリンが生成して蛍光を生じるため、蛍光測定によりアロマターゼ活性促進能の定量を行った。   Fluorescence measurement was performed at an excitation wavelength of 409 nm and an emission wavelength of 530 nm. Since 7-methoxy-4-trifluoromethylcoumarin is decomposed by CYP19 and 7-hydroxy-4-trifluoromethylcoumarin is generated to produce fluorescence, the aromatase activity promoting ability was quantified by fluorescence measurement.

得られた結果を、試料無添加のコントロールにおけるアロマターゼ活性促進作用を100としたときの相対値により、表5に示す。   The obtained results are shown in Table 5 as relative values when the aromatase activity promoting action in the control without addition of the sample is taken as 100.

Figure 0005025201
Figure 0005025201

表5より明らかなように、試料を添加した場合には、有意なアロマターゼ活性促進作用が認められた。   As is apparent from Table 5, when the sample was added, a significant aromatase activity promoting action was observed.

<表皮メラニン細胞チロシナーゼ活性阻害作用の評価>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のように表皮メラニン細胞チロシナーゼ活性阻害作用を評価した。
<Evaluation of epidermal melanocyte tyrosinase activity inhibitory action>
Using the ethanol extract obtained by the extraction method 1 as a sample, the epidermal melanocyte tyrosinase activity inhibitory action was evaluated as follows.

正常ヒト表皮メラニン細胞を、1ウェルあたり3.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、倉敷紡績(株)製Medium 154Sを用いた。24時間培養後、Medium 154Sにより表6に示す各試料濃度に調整したサンプル培養液に交換し、さらに48時間培養した。次に1質量%Triton−Xを含有するリン酸緩衝液75μlに交換して細胞を完全に溶解させ、内50μlを粗酵素液として使用した。粗酵素液に、基質となる0.05質量%L−ドーパ含有リン酸緩衝液50μlを加え、37℃で2時間静置した。マイクロプレートリーダーにより、基質添加直後と反応終了時の405nmの吸光度を測定し、各測定値を次式に導入して、生成されたドーパメラニン量を求めた。 Normal human epidermal melanocytes were seeded in a 96-well microplate so that there were 3.0 × 10 4 cells per well. As a seeding medium, Medium 154S manufactured by Kurashiki Boseki Co., Ltd. was used. After culturing for 24 hours, the medium was replaced with a sample culture solution adjusted to each sample concentration shown in Table 6 using Medium 154S, and further cultured for 48 hours. Next, the cells were completely lysed by exchanging with 75 μl of a phosphate buffer containing 1% by weight Triton-X, and 50 μl of this was used as a crude enzyme solution. To the crude enzyme solution, 50 μl of 0.05% by mass L-dopa-containing phosphate buffer as a substrate was added and allowed to stand at 37 ° C. for 2 hours. The absorbance at 405 nm immediately after the addition of the substrate and at the end of the reaction was measured with a microplate reader, and each measured value was introduced into the following equation to determine the amount of produced dopamelanin.

ドーパメラニン生成量=
{(反応後405nm値−反応前405nm値)−2.166}/5.238
また、PIERCE社製BCA Protein Assay Kitによりタンパク量を測定し、単位タンパク量当りのメラニン生成量を求めた。得られたメラニン産生量に基づいて試料無添加の場合に対する阻害率を算定し、結果を表6に示す。
Dopamelanin production =
{(405 nm value after reaction−405 nm value before reaction) −2.166} /5.238
Moreover, the amount of protein was measured by BCA Protein Assay Kit made by PIERCE, and the amount of melanin produced per unit protein amount was determined. Based on the amount of melanin produced, the inhibition rate with respect to the case where no sample was added was calculated.

Figure 0005025201
Figure 0005025201

表6より明らかなように、試料を添加した培地では、メラニン産生の低下が認められ、優れたチロシナーゼ活性阻害作用が認められた。   As is clear from Table 6, in the medium to which the sample was added, a decrease in melanin production was observed, and an excellent tyrosinase activity inhibitory effect was observed.

<ヒアルロニダーゼ阻害作用の評価)>
上記抽出方法1で得られたエタノール抽出物を試料として、以下のようにヒアルロニダーゼ阻害作用を評価した。
<Evaluation of hyaluronidase inhibitory action>
Using the ethanol extract obtained by the extraction method 1 as a sample, the hyaluronidase inhibitory action was evaluated as follows.

市販のヒアルロン酸カリウム塩(ヒト臍の緒由来)を0.9mg/mlになるように、0.1Mリン酸緩衝液(pH7.0)に溶解し、基質溶液とした。市販のヒアルロニダーゼ(ウシ精巣由来)を5,300 unit/mlとなるように、0.1Mリン酸緩衝液(pH7.0)に溶解し、酵素溶液とした。酵素溶液は用時調製とした。   Commercially available hyaluronic acid potassium salt (derived from human umbilical cord) was dissolved in 0.1 M phosphate buffer (pH 7.0) to a concentration of 0.9 mg / ml to obtain a substrate solution. A commercially available hyaluronidase (derived from bovine testis) was dissolved in 0.1 M phosphate buffer (pH 7.0) so as to be 5,300 units / ml to obtain an enzyme solution. The enzyme solution was prepared at the time of use.

緩衝液で表7に示す各試料濃度に調製した溶液0.1ml、および酵素溶液0.03mlを試験管に入れ、37℃で20分間反応させた。次に、活性化剤を0.06ml加え、37℃で20分間反応させた。さらに、基質溶液を0.15ml加え、37℃で1時間反応させた。0.4NのNaOH水溶液0.06mlを加えて反応を停止させた後、すぐに氷冷し、ホウ酸緩衝液(pH9.1)を0.06ml添加し、3分間煮沸した後、さらに氷冷した。p−DABA(p−ジメチルアミノベンズアルデヒド)溶液を2.0ml添加し、37℃で20分間反応させた後、各試験管から96ウェルマイクロプレートに移しかえ、マイクロプレートリーダーを用いて585nmにおける吸光度を測定した。コントロールには、サンプル無添加の緩衝溶液を用いた。ヒアルロニダーゼの活性が阻害されると、分解産物であるN−アセチルグルコサミン(GlcNAc)が減少し、p−DABAによる吸光度が低くなる。ヒアルロニダーゼ阻害作用は、次式に定義される。   0.1 ml of the solution prepared to each sample concentration shown in Table 7 with buffer and 0.03 ml of enzyme solution were put in a test tube and reacted at 37 ° C. for 20 minutes. Next, 0.06 ml of activator was added and reacted at 37 ° C. for 20 minutes. Further, 0.15 ml of the substrate solution was added and reacted at 37 ° C. for 1 hour. The reaction was stopped by adding 0.06 ml of 0.4N NaOH aqueous solution, immediately cooled on ice, 0.06 ml of borate buffer (pH 9.1) was added and boiled for 3 minutes. did. After 2.0 ml of p-DABA (p-dimethylaminobenzaldehyde) solution was added and reacted at 37 ° C. for 20 minutes, the solution was transferred from each test tube to a 96-well microplate, and the absorbance at 585 nm was measured using a microplate reader. It was measured. As a control, a sample-free buffer solution was used. When the activity of hyaluronidase is inhibited, the degradation product N-acetylglucosamine (GlcNAc) is decreased, and the absorbance by p-DABA is lowered. The hyaluronidase inhibitory action is defined by the following formula.

阻害率(%)
=(コントロール吸光度−サンプル吸光度)/コントロール吸光度×100
結果を表7に示す。
Inhibition rate (%)
= (Control absorbance-sample absorbance) / control absorbance x 100
The results are shown in Table 7.

Figure 0005025201
Figure 0005025201

表7より明らかなように、試料を添加した場合には、優れたヒアルロニダーゼ活性の阻害作用が認められた。   As is apparent from Table 7, when the sample was added, an excellent inhibitory effect on hyaluronidase activity was observed.

<DPPHラジカル消去による抗酸化作用の評価>
上記抽出方法1もしくは抽出方法2で得られた抽出物を試料として、以下のようにDPPHラジカル消去による抗酸化作用を評価した。
<Evaluation of antioxidant effect by scavenging DPPH radical>
Using the extract obtained by the extraction method 1 or the extraction method 2 as a sample, the antioxidant action by DPPH radical elimination was evaluated as follows.

50質量%エタノールを用いて、表8に示す各試料濃度となるように試料溶液を調整し、96ウェルマイクロプレートに100μlずつ添加した。そこへ、0.2mMの1,1−ジフェニル−2−ピクリルヒドラジル(DPPH)エタノール溶液を100μlずつ添加し、よく混合後、室温、暗所にて24時間静置した。最後に、DPPHラジカルに由来する516nmの吸光度を測定した。   Using 50% by mass ethanol, the sample solution was adjusted so as to have each sample concentration shown in Table 8, and 100 μl was added to each 96-well microplate. Thereto was added 100 μl of 0.2 mM 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution, mixed well, and allowed to stand at room temperature in the dark for 24 hours. Finally, the absorbance at 516 nm derived from the DPPH radical was measured.

試料を添加しなかった場合の吸光度を(A)、試料を添加した場合の吸光度を(B)としたとき、DPPHラジカルの消去率を次式より求めた。   When the absorbance when the sample was not added was (A) and the absorbance when the sample was added was (B), the DPPH radical elimination rate was determined from the following equation.

ラジカル消去率={1−(B)/(A)}×100
結果を表8に示す。
Radical scavenging rate = {1- (B) / (A)} × 100
The results are shown in Table 8.

Figure 0005025201
Figure 0005025201

表8より明らかなように、試料を添加した場合には、優れたDPPHラジカル消去効果が認められた。   As is apparent from Table 8, when the sample was added, an excellent DPPH radical scavenging effect was observed.

<SOD様活性評価(スーパーオキサイドアニオン消去能の評価)>
上記抽出方法2で得られた熱水抽出物を試料として、以下のようにSOD様活性を評価した。
<SOD-like activity evaluation (evaluation of superoxide anion scavenging ability)>
Using the hot water extract obtained by the extraction method 2 as a sample, SOD-like activity was evaluated as follows.

0.25mM WST−1および1mM Hypoxanthineを含むHANK’S(+)溶液75μlに、HANK’S(+)溶液により表9に示す各試料濃度に調製したサンプル溶液25μlを添加した。さらに、キサンチンオキシダーゼ25μl(0.0075 Units)を添加し、37℃、15分間反応させた後、450nmの吸光度を測定した。サンプル溶液に代えてHANK’S(+)溶液のみを添加した場合の吸光度を(A)、サンプル溶液を添加した場合の吸光度を(B)としたとき、スーパーオキサイドアニオン消去率は次式に定義される。   To 75 μl of the HANK ′S (+) solution containing 0.25 mM WST-1 and 1 mM Hypoxanthine, 25 μl of the sample solution prepared by the HANK ′S (+) solution to each sample concentration shown in Table 9 was added. Further, 25 μl (0.0075 Units) of xanthine oxidase was added and reacted at 37 ° C. for 15 minutes, and then the absorbance at 450 nm was measured. The superoxide anion elimination rate is defined by the following equation, where (A) is the absorbance when only the HANK'S (+) solution is added instead of the sample solution, and (B) is the absorbance when the sample solution is added. Is done.

消去率(%)={1−(B)/(A)}×100
得られた結果を表9に示す。
Erase rate (%) = {1- (B) / (A)} × 100
Table 9 shows the obtained results.

Figure 0005025201
Figure 0005025201

表9より明らかなように、試料を添加した場合には、優れたスーパーオキサイドアニオン消去効果が認められた。   As is clear from Table 9, when the sample was added, an excellent superoxide anion erasing effect was observed.

続いて、本発明に係るサガリバナ属植物もしくはホウガンノキ属植物の抽出物を配合した組成物として、皮膚外用剤と食品の処方例を示す。   Then, the formulation example of a skin external preparation and a foodstuff is shown as a composition which mix | blended the extract of the genus Sagaribana or the genus Botanus concerning the present invention.

[処方例1]乳液
(1)スクワラン 10.0(重量%)
(2)メチルフェニルポリシロキサン 4.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)モノステアリン酸ポリオキシエチレン
ソルビタン(20E.O.) 1.3
(6)モノステアリン酸ソルビタン 1.0
(7)グリセリン 4.0
(8)パラオキシ安息香酸メチル 0.1
(9)カルボキシビニルポリマー 0.15
(10)精製水 53.85
(11)アルギニン(1重量%水溶液) 20.0
(12)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、冷却を開始し、(11)と(12)を順次加え、均一に混合する。
[Formulation Example 1] Emulsion (1) Squalane 10.0 (wt%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 53.85
(11) Arginine (1 wt% aqueous solution) 20.0
(12) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) sequentially and mix uniformly.

[処方例2]化粧水
(1)エタノール 15.0(重量%)
(2)ポリオキシエチレン(40E.O.)硬化ヒマシ油 0.3
(3)香料 0.1
(4)精製水 78.38
(5)クエン酸 0.02
(6)クエン酸ナトリウム 0.1
(7)グリセリン 1.0
(8)ヒドロキシエチルセルロース 0.1
(9)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)に(2)及び(3)を溶解する。溶解後、(4)〜(8)を順次添加した後、十分に攪拌し、(9)を加え、均一に混合する。
[Prescription Example 2] Lotion (1) Ethanol 15.0 (% by weight)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 78.38
(5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, (9) is added and mixed uniformly.

[処方例3]クリーム
(1)スクワラン 10.0(重量%)
(2)ステアリン酸 2.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)セタノール 3.6
(6)親油型モノステアリン酸グリセリン 2.0
(7)グリセリン 10.0
(8)パラオキシ安息香酸メチル 0.1
(9)アルギニン(20重量%水溶液) 15.0
(10)精製水 36.7
(11)カルボキシビニルポリマー(1重量%水溶液) 15.0
(12)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、(11)を加え、冷却を開始し、40℃にて(12)を加え、均一に混合する。
[Prescription Example 3] Cream (1) Squalane 10.0 (% by weight)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by weight aqueous solution) 15.0
(10) Purified water 36.7
(11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification is completed, add (11), start cooling, add (12) at 40 ° C., and mix uniformly.

[処方例4]美容液
(1)精製水 27.45(重量%)
(2)グリセリン 10.0
(3)ショ糖脂肪酸エステル 1.3
(4)カルボキシビニルポリマー(1重量%水溶液) 17.5
(5)アルギン酸ナトリウム(1重量%水溶液) 15.0
(6)モノラウリン酸ポリグリセリル 1.0
(7)マカデミアナッツ油脂肪酸フィトステリル 3.0
(8)N-ラウロイル-L-グルタミン酸
ジ(フィトステリル−2−オクチルドデシル) 2.0
(9)硬化パーム油 2.0
(10)スクワラン(オリーブ由来) 1.0
(11)ベヘニルアルコール 0.75
(12)ミツロウ 1.0
(13)ホホバ油 1.0
(14)1、3−ブチレングリコール 10.0
(15)L−アルギニン(10重量%水溶液) 2.0
(16)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)〜(6)の水相成分を混合し、75℃にて加熱溶解する。一方、(7)〜(14)の油相成分を混合し、75℃にて加熱溶解する。次いで、上記水相成分に油相成分を添加して予備乳化を行った後、ホモミキサーにて均一に乳化する。乳化終了後に冷却を開始し、50℃にて(15)を加える。さらに40℃まで冷却し、(16)を加え、均一に混合する。
[Formulation Example 4] Cosmetic liquid (1) Purified water 27.45 (% by weight)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by weight aqueous solution) 17.5
(5) Sodium alginate (1 wt% aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (from olive) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by weight aqueous solution) 2.0
(16) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: The aqueous phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Cooling is started after completion of emulsification, and (15) is added at 50 ° C. Cool further to 40 ° C, add (16) and mix evenly.

[処方例5]水性ジェル
(1)カルボキシビニルポリマー 0.5(重量%)
(2)精製水 78.7
(3)水酸化ナトリウム(10重量%水溶液) 0.5
(4)エタノール 10.0
(5)パラオキシ安息香酸メチル 0.1
(6)香料 0.1
(7)コバンノアシ抽出物(葉)[抽出方法1] 10.0
(8)ポリオキシエチレン(60E.O.)硬化ヒマシ油 0.1
製法:(1)を(2)に加え、均一に攪拌した後、(3)を加える。均一に攪拌した後、(4)に予め溶解した(5)を加える。均一に攪拌した後、予め混合しておいた(6)〜(8)を加え、均一に攪拌混合する。
[Formulation Example 5] Aqueous gel (1) Carboxyvinyl polymer 0.5 (% by weight)
(2) Purified water 78.7
(3) Sodium hydroxide (10% by weight aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Cobannoashi extract (leaves) [Extraction method 1] 10.0
(8) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, the previously mixed (6) to (8) are added and stirred and mixed uniformly.

[処方例6]クレンジング料
(1)スクワラン 77.0(重量%)
(2)イソステアリン酸ポリオキシエチレングリセリル 15.0
(3)精製水 3.0
(4)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)と(2)を均一に溶解する。これに、(3)と(4)を順次加え、均一に混合する。
[Formulation Example 6] Cleansing Fee (1) Squalane 77.0 (wt%)
(2) Polyoxyethylene glyceryl isostearate 15.0
(3) Purified water 3.0
(4) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Manufacturing method: (1) and (2) are uniformly dissolved. (3) and (4) are sequentially added to this and mixed uniformly.

[処方例7]洗顔フォーム
(1)ステアリン酸 16.0(重量%)
(2)ミリスチン酸 16.0
(3)親油型モノステアリン酸グリセリン 2.0
(4)グリセリン 20.0
(5)水酸化ナトリウム 7.5
(6)ヤシ油脂肪酸アミドプロピルベタイン 1.0
(7)精製水 31.5
(8)コバンノアシ抽出物(葉)[抽出方法1] 6.0
製法:(1)〜(4)の油相成分を80℃にて加熱溶解する。一方(5)〜(7)の水相成分を80℃にて加熱溶解し、油相成分と均一に混合撹拌する。冷却を開始し、40℃にて(8)を加え、均一に混合する。
[Prescription Example 7] Face-wash foam (1) Stearic acid 16.0 (% by weight)
(2) Myristic acid 16.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Glycerin 20.0
(5) Sodium hydroxide 7.5
(6) Palm oil fatty acid amidopropyl betaine 1.0
(7) Purified water 31.5
(8) Cobannoashi extract (leaves) [Extraction method 1] 6.0
Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (5) to (7) are heated and dissolved at 80 ° C., and mixed and stirred uniformly with the oil phase components. Cooling is started, and (8) is added at 40 ° C. and mixed uniformly.

[処方例8]メイクアップベースクリーム
(1)スクワラン 10.2(重量%)
(2)セタノール 2.0
(3)グリセリントリ−2−エチルヘキサン酸エステル 2.5
(4)親油型モノステアリン酸グリセリル 1.0
(5)プロピレングリコール 11.0
(6)ショ糖脂肪酸エステル 1.3
(7)精製水 65.4
(8)酸化チタン 1.0
(9)ベンガラ 0.1
(10)黄酸化鉄 0.4
(11)香料 0.1
(12)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)〜(4)の油相成分を混合し、75℃にて加熱溶解する。一方、(5)〜(7)の水相成分を混合し、75℃にて加熱溶解し、これに(8)〜(10)の顔料を加え、ホモミキサーにて均一に分散させる。この水相成分に前記油相成分を加え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、40℃にて(11)と(12)の成分を加え、均一に混合する。
[Prescription Example 8] Make-up base cream (1) Squalane 10.2 (% by weight)
(2) Cetanol 2.0
(3) Glycerin tri-2-ethylhexanoate 2.5
(4) Lipophilic glyceryl monostearate 1.0
(5) Propylene glycol 11.0
(6) Sucrose fatty acid ester 1.3
(7) Purified water 65.4
(8) Titanium oxide 1.0
(9) Bengala 0.1
(10) Yellow iron oxide 0.4
(11) Fragrance 0.1
(12) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: The oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C., and the pigments (8) to (10) are added thereto and dispersed uniformly with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[処方例9]乳液状ファンデーション
(1)メチルポリシロキサン 2.0(重量%)
(2)スクワラン 5.0
(3)ミリスチン酸オクチルドデシル 5.0
(4)セタノール 1.0
(5)ポリオキシエチレン(20E.O.)
ソルビタンモノステアリン酸エステル 1.3
(6)モノステアリン酸ソルビタン 0.7
(7)1、3−ブチレングリコール 8.0
(8)キサンタンガム 0.1
(9)パラオキシ安息香酸メチル 0.1
(10)精製水 53.4
(11)酸化チタン 9.0
(12)タルク 7.4
(13)ベンガラ 0.5
(14)黄酸化鉄 1.1
(15)黒酸化鉄 0.1
(16)香料 0.1
(17)コバンノアシ抽出物(葉)[抽出方法1] 5.0
製法:(1)〜(6)の油相成分を混合し、75℃にて加熱溶解する。一方、(7)〜(10)の水相成分を混合し、75℃にて加熱溶解し、これに(11)〜(15)の顔料を加え、ホモミキサーにて均一に分散する。油相成分を加え、乳化を行う。乳化終了後に冷却を開始し、40℃にて(16)と(17)の成分を順次加え、均一に混合する。
[Formulation Example 9] Emulsion foundation (1) Methylpolysiloxane 2.0 (wt%)
(2) Squalane 5.0
(3) Octyldodecyl myristate 5.0
(4) Cetanol 1.0
(5) Polyoxyethylene (20E.O.)
Sorbitan monostearate 1.3
(6) Sorbitan monostearate 0.7
(7) 1,3-butylene glycol 8.0
(8) Xanthan gum 0.1
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 53.4
(11) Titanium oxide 9.0
(12) Talc 7.4
(13) Bengala 0.5
(14) Yellow iron oxide 1.1
(15) Black iron oxide 0.1
(16) Fragrance 0.1
(17) Cobannoashi extract (leaves) [Extraction method 1] 5.0
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and dissolved by heating at 75 ° C., and the pigments (11) to (15) are added thereto and uniformly dispersed with a homomixer. Add oil phase ingredients and emulsify. Cooling is started after the emulsification is completed, and components (16) and (17) are sequentially added at 40 ° C. and mixed uniformly.

[処方例10]油中水型エモリエントクリーム
(1)流動パラフィン 30.0(重量%)
(2)マイクロクリスタリンワックス 2.0
(3)ワセリン 5.0
(4)ジグリセリンオレイン酸エステル 5.0
(5)塩化ナトリウム 1.3
(6)塩化カリウム 0.1
(7)プロピレングリコール 3.0
(8)1、3−ブチレングリコール 5.0
(9)パラオキシ安息香酸メチル 0.1
(10)コバンノアシ抽出物(葉)[抽出方法1] 5.0
(11)精製水 43.4
(12)香料 0.1
製法:(5)と(6)を(11)の一部に溶解して50℃とし、50℃に加熱した(4)に撹拌しながら徐々に加える。これを混合した後、70℃にて加熱溶解した(1)〜(3)に均一に分散する。これに(7)〜(10)を(11)の残部に70℃にて加熱溶解したものを撹拌しながら加え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、40℃にて(12)を加え、均一に混合する。
[Formulation Example 10] Water-in-oil emollient cream (1) Liquid paraffin 30.0 (% by weight)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglycerin oleate 5.0
(5) Sodium chloride 1.3
(6) Potassium chloride 0.1
(7) Propylene glycol 3.0
(8) 1,3-butylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Cobannoashi extract (leaves) [Extraction method 1] 5.0
(11) Purified water 43.4
(12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C., and gradually add to (4) heated to 50 ° C. with stirring. After mixing this, it disperse | distributes uniformly to (1)-(3) heated and melt | dissolved at 70 degreeC. (7) to (10) are added to the remainder of (11) heated and dissolved at 70 ° C. while stirring and emulsified with a homomixer. Cooling is started after completion of emulsification, and (12) is added at 40 ° C. and mixed uniformly.

[処方例11]パック
(1)精製水 58.9(重量%)
(2)ポリビニルアルコール 12.0
(3)エタノール 17.0
(4)グリセリン 5.0
(5)ポリエチレングリコール(平均分子量1000) 2.0
(6)コバンノアシ抽出物(葉)[抽出方法1] 5.0
(7)香料 0.1
製法:(2)と(3)を混合し、80℃に加温した後、80℃に加温した(1)に溶解する。均一に溶解した後、(4)と(5)を加え、攪拌しながら冷却を開始する。40℃まで冷却し、(6)と(7)を加え、均一に混合する。
[Prescription Example 11] Pack (1) Purified water 58.9 (% by weight)
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Cobannoashi extract (leaves) [Extraction method 1] 5.0
(7) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C, add (6) and (7) and mix uniformly.

[処方例12]入浴剤
(1)香料 0.3(重量%)
(2)コバンノアシ抽出物(葉)[抽出方法1] 5.0
(3)炭酸水素ナトリウム 46.0
(4)硫酸ナトリウム 48.7
製法:(1)〜(4)を均一に混合する。
[Prescription Example 12] Bath agent (1) Fragrance 0.3 (% by weight)
(2) Cobannoashi extract (leaves) [Extraction method 1] 5.0
(3) Sodium bicarbonate 46.0
(4) Sodium sulfate 48.7
Production method: (1) to (4) are mixed uniformly.

[処方例13]ヘアーワックス
(1)ステアリン酸 3.0(重量%)
(2)マイクロクリスタリンワックス 2.0
(3)セチルアルコール 3.0
(4)高重合メチルポリシロキサン 2.0
(5)メチルポリシロキサン 5.0
(6)ポリ(オキシエチレン・オキシプロピレン)
メチルポリシロキサン共重合体 1.0
(7)パラオキシ安息香酸メチル 0.1
(8)1、3−ブチレングリコール 7.5
(9)アルギニン 0.7
(10)精製水 70.6
(11)コバンノアシ抽出物(葉)[抽出方法2] 5.0
(12)香料 0.1
製法:(1)〜(6)の油相成分を混合し、75℃にて加熱溶解後する。一方、(7)〜(10)の水相成分を75℃にて加熱溶解し、前記油相成分を加え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、40℃にて(11)と(12)の成分を加え、均一に混合する。
[Prescription Example 13] Hair wax (1) Stearic acid 3.0 (% by weight)
(2) Microcrystalline wax 2.0
(3) Cetyl alcohol 3.0
(4) Highly polymerized methylpolysiloxane 2.0
(5) Methylpolysiloxane 5.0
(6) Poly (oxyethylene / oxypropylene)
Methylpolysiloxane copolymer 1.0
(7) Methyl paraoxybenzoate 0.1
(8) 1,3-butylene glycol 7.5
(9) Arginine 0.7
(10) Purified water 70.6
(11) Cobannoashi extract (leaves) [Extraction method 2] 5.0
(12) Fragrance 0.1
Production method: The oil phase components (1) to (6) are mixed and heated and dissolved at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 75 ° C., the oil phase component is added, and the mixture is emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[処方例14]ヘアートニック
(1)エタノール 46.0(重量%)
(2)精製水 48.9
(3)コバンノアシ抽出物(葉)[抽出方法1] 5.0
(4)香料 0.1
製法:(1)〜(4)の成分を混合、均一化する。
[Prescription Example 14] Hair artic (1) Ethanol 46.0 (% by weight)
(2) Purified water 48.9
(3) Cobannoashi extract (leaves) [Extraction method 1] 5.0
(4) Fragrance 0.1
Production method: Components (1) to (4) are mixed and homogenized.

[処方例15]飲料
(1)コバンノアシ抽出物(葉)[抽出方法1] 8.0(重量%)
(2)エリスリトール 1.0
(3)クエン酸 0.1
(4)ステビア 0.01
(5)精製水 90.89
製法:(1)〜(5)を均一に混合する。
[Prescription Example 15] Beverage (1) Cobannoashi Extract (Leaf) [Extraction Method 1] 8.0 (wt%)
(2) Erythritol 1.0
(3) Citric acid 0.1
(4) Stevia 0.01
(5) Purified water 90.89
Production method: (1) to (5) are mixed uniformly.

[処方例16]錠剤
(1)コバンノアシ抽出物(葉)[抽出方法2] 0.30(重量部)
(2)還元麦芽糖水飴 0.53
(3)トウモロコシデンプン 0.15
(4)グリセリン脂肪酸エステル 0.02
製法:(1)〜(3)を篩過して混合し、さらに(4)を添加して混合した。打錠機にて打錠を行い、全量300mgの錠剤を得た。
[Prescription Example 16] Tablet (1) Cobannoashi extract (leaves) [Extraction method 2] 0.30 (parts by weight)
(2) Reduced maltose starch syrup 0.53
(3) Corn starch 0.15
(4) Glycerin fatty acid ester 0.02
Production method: (1) to (3) were sieved and mixed, and (4) was further added and mixed. Tableting was performed with a tableting machine to obtain tablets with a total amount of 300 mg.

次に、サガリバナ属植物もしくはホウガンノキ属植物の抽出物を配合した処方を用いて使用試験を行い、乾燥による肌荒れについて改善効果を評価した。その際、処方例1に示した乳液の処方に表10に記載する試料をそれぞれ配合し、実施例1〜3として使用試験を行った。また、試料を精製水に代替し、比較例1として同時に使用試験を行った。   Next, a use test was conducted using a prescription blended with an extract of a genus Sagaribana or a genus plant, and the effect of improving skin roughness due to drying was evaluated. At that time, the samples shown in Table 10 were blended with the emulsion formulation shown in Formulation Example 1, and the use test was conducted as Examples 1 to 3. Further, the sample was replaced with purified water, and a use test was conducted simultaneously as Comparative Example 1.

Figure 0005025201
Figure 0005025201

各試料について、肌荒れ症状が顕著に認められる30〜50才代の乾燥肌の女性パネラー20名をそれぞれ一群とし、ブラインドにて1週間使用させ、使用前後の皮膚状態の変化を観察して評価した。皮膚症状の指標として、乾燥による肌荒れについて、「改善」、「やや改善」、「変化なし」の三段階で評価し、表11に各評価を得たパネラー数にて示した。   For each sample, 20 female panelists with dry skin in their 30s to 50s whose skin symptom was remarkably recognized were grouped and used blindly for 1 week, and the skin condition before and after use was observed and evaluated. . As an index of skin symptom, rough skin due to dryness was evaluated in three stages of “improved”, “slightly improved”, and “no change”, and Table 11 shows the number of panelists that obtained each evaluation.

Figure 0005025201
Figure 0005025201

表11より、試料を配合した実施例使用群においては、明確な肌荒れの改善が認められた。このことから、サガリバナ属植物もしくはホウガンノキ属植物の抽出物は優れた保湿効果を有することが明らかとなった。   From Table 11, in the Example use group which mix | blended the sample, clear improvement of rough skin was recognized. From this, it has been clarified that the extract of the genus Sagaribana or the genus Botanus has an excellent moisturizing effect.

Claims (2)

サガリバナ属植物もしくはホウガンノキ属植物より選ばれる1種又は2種以上の植物の抽出物を有効成分とする保湿剤。 A moisturizing agent comprising as an active ingredient an extract of one or more plants selected from a plant belonging to the genus Sagaribana or a genus Botanus. サガリバナ属植物もしくはホウガンノキ属植物より選ばれる1種又は2種以上の植物の抽出物を有効成分とする抗酸化剤The antioxidant which uses the extract of the 1 type, or 2 or more types of plant chosen from Sagaribana genus plant or Botanus genus plant as an active ingredient.
JP2006253556A 2006-09-19 2006-09-19 Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant Active JP5025201B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006253556A JP5025201B2 (en) 2006-09-19 2006-09-19 Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant
PCT/JP2007/067415 WO2008035572A1 (en) 2006-09-19 2007-09-06 Moisturizing agent, anti-aging agent, skin-whitening agent, antiinflammatory agent, and antioxidant agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006253556A JP5025201B2 (en) 2006-09-19 2006-09-19 Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant

Publications (2)

Publication Number Publication Date
JP2008074730A JP2008074730A (en) 2008-04-03
JP5025201B2 true JP5025201B2 (en) 2012-09-12

Family

ID=39200399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006253556A Active JP5025201B2 (en) 2006-09-19 2006-09-19 Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant

Country Status (2)

Country Link
JP (1) JP5025201B2 (en)
WO (1) WO2008035572A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304323B1 (en) * 2007-03-30 2009-08-13 Caroi'line Cosmetica, S.L. EXTRACT OF THE COUROUPITA GUIANENSIS SHEETS, PROCEDURE OF OBTAINING AND ITS COSMETIC USE AS AN ANTIOXIDANT / ANTIRRADICALARY / UV FILTER.
US20130195925A1 (en) * 2011-11-03 2013-08-01 Vaskin, Llc Anti aging application and method for treating aging

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756390B1 (en) * 1996-11-22 2002-11-15 Mesura Ets APPARATUS FOR AUTOMATIC GAS PRESSURE REGULATION
FR2757390B1 (en) * 1996-12-20 1999-03-12 Dior Christian Parfums USE OF AN EXTRACT FROM THE PLANT BARRINGTONIA, IN THE COSMETIC AND PHARMACEUTICAL AREAS, ESPECIALLY DERMATOLOGICAL

Also Published As

Publication number Publication date
JP2008074730A (en) 2008-04-03
WO2008035572A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
JP2008063266A (en) Anti-aging agent, bleaching agent, anti-oxidizing agent and anti-inflammatory agent
JP5557414B2 (en) Moisturizer, cell activator, and whitening agent
JP5014343B2 (en) Nemagaridake-containing composition, moisturizer, cell activator, whitening agent and antioxidant
JP5025201B2 (en) Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant
JP4201091B1 (en) Moisturizer, anti-aging agent, antioxidant and external preparation for skin
JP5312731B2 (en) Topical skin preparation
JP5062980B2 (en) Moisturizer, collagen production promoter, whitening agent, antioxidant, and vascular endothelial growth factor production promoter
JP4689215B2 (en) Moisturizer, cell activator, whitening agent, and collagenase inhibitor
JP2007277100A (en) Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor
JP4748962B2 (en) Moisturizer, cell activator, whitening agent, and antioxidant
JP4970442B2 (en) Whitening agent
JP4931452B2 (en) Moisturizer, cell activator, whitening agent, and antioxidant
JP4994684B2 (en) Moisturizer, cell activator, and antioxidant
JP4515425B2 (en) Moisturizer, cell activator, whitening agent, and antioxidant
JP4050727B2 (en) Moisturizer, cell activator, whitening agent, antioxidant, and skin external preparation
JP4515423B2 (en) Moisturizer, cell activator, and antioxidant
JP4480366B2 (en) Cell activator, whitening agent, hyaluronic acid production promoter, collagen production promoter, antioxidant, and skin external preparation
JP4936754B2 (en) Moisturizer, cell activator, and collagenase inhibitor
JP5009544B2 (en) Moisturizer, cell activator, antioxidant, and collagenase inhibitor
JP5656348B2 (en) Moisturizer, anti-aging agent, antioxidant, immunostimulant, whitening agent, skin external preparation, functional oral composition
JP5013726B2 (en) Moisturizer, cell activator, antioxidant, and collagenase inhibitor
JP4869638B2 (en) Cell activator, whitening agent, antioxidant, amylase inhibitor, and humectant
JP5388555B2 (en) Moisturizer, anti-aging agent, antioxidant, slimming agent, whitening agent, anti-inflammatory agent, immunostimulant, external preparation for skin, functional oral composition
JP5241395B2 (en) Moisturizer, immunostimulant, anti-aging agent, anti-inflammatory agent, antioxidant, whitening agent
JP4166790B2 (en) Moisturizer, ATP production promoter, whitening agent, antioxidant, neutral fat accumulation inhibitor, and collagen production promoter

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120619

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120619

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5025201

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250